Kristin Abate - 01 Oct 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role: Chief Accounting Officer
Signature: /s/ Nancy Smith as Attorney-in-Fact for Kristin Abate
Issuer symbol: KPTI
Transactions as of: 01 Oct 2025
Net transactions value: -$2,279
Form type: 4
Filing time: 03 Oct 2025, 16:56:19 UTC
Previous filing: 16 Sep 2025
Next filing: 16 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Abate Kristin	Chief Accounting Officer	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON	/s/ Nancy Smith as Attorney-in-Fact for Kristin Abate	03 Oct 2025	0002045943

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPTI	Common Stock	Sale	$2,279	-362	-3.5%	$6.30	10,046	01 Oct 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
F2	Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.19 to $6.30, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.